Introducing BIO's Next-Generation Partnering System, Opening April 2015

A newly released study, commissioned by the Biotechnology Industry Organization (BIO), documents the significant impact academic technology transfer makes on the U.S. economy.

What is cloning?

Animal reproductive technologies — the forerunners of cloning — have been rigorously studied for decades. The U.S. Food and Drug Administration analyzed over 400 scientific studies on cloning, conducted over many years and encompassing several generations and large families of livestock. The National Academy of Sciences has also scrutinized this topic, publishing reviews in 2002 and 2004.

Thank you for your interest! Click below to download your copy of BIO's "Venture Funding of Therapeutic Innovation: A Comprehensive Look at a Decade of Venture Funding of Drug R&D".

Thank you, your suggestion has been submitted.

Clone Safety is committed to providing the public and the press with timely and accurate information about animal cloning that is backed by rigorous scientific research.

For more than a decade, BIO has called for open, transparent, and science-based dialogue regarding biosimilars. More recently, we played a leading role in the effort to establish a pathway for the approval of biosimilars. Many of our members are global leaders in the development and commercialization of biosimilars.

Industrial Biotechnology companies have demonstrated visible progress in the commercialization of advanced biofuels, biobased products and renewable chemicals.  A link to these examples is provided.

Governor of Washington Jay Inslee and Governor of California Edmund Brown wrote a letter to EPA Administrator Gina McCarthy and OMB Director Shaun Donovan, urging them to adopt a final federal Renewable Fuel Standard 2 (RFS2) 2014 rule.

The second letter noted is from Illinois Govenor Pat Quinn and Iowa Govenor Terry Branstad to OMB Director Shaun Donovan expressing concern that the EPA's proposed cuts to the 2014 RFS requirements will have a negative impact on the rural economy and on the biofuels industry.  

On October 8, 2014, Massachusetts Senator Edward Markey (D) and California Senator Barbara Boxer (D) issued a letter to President Barack Obama expressing concerns around the 2014 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard (RFS) proposed by the Environmental Protection Agency (EPA).

Thank you, your RSVP submission has been received.

Thank you for submitting your room request for the 2015 JP Morgan Healthcare Conference. Our customer service team will respond to your request within 2 business days. 

For questions, please contact Willie Reaves at biopartnering(at) or 202-905-2276.

Thank you for submitting your BIO Board and Section-Level Committee Designation form. The relevant BIO committee representative (s) will contact you soon to confirm your committee assignments.

Patient requests for access to drugs and biologics prior to their approval have long created a dilemma for biotechnology companies.

Thank you for registering for the 2015 CSBA/SGRC Retreat! If you have any question please contact Brian Stoker at

All BIO members benefit from access to networking opportunities, members’ only committees, as well as discounts at conferences and on business services and supplies from major brands. In addition to the standard member benefits, BIO is pleased to offer unique and recently expanded benefits to its law firms members.

BIO Business Solutions

Chair: Adam Monroe, President-Americas, Novozymes 
Staff Contact: Brent Erickson, Executive Vice President, Industrial & Environmental, berickson(@)  

Co-Chair: Timothy Cooke, Chief Executive Officer, Novadigm Therapeutics, Inc.
Co-Chair: Angela Hwang, US Regional Lead, Pfizer, Inc.
Staff Contact: Phyllis Arthur, Senior Director, Vaccines, Immunotherapetuics and Diagnostics Policy, parthur(at)

Co-Chair: Richard Pops, Chairman & CEO, Alkermes, plc
Co-Chair: John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Staff Contact: Andrew Emmett, Managing Director for Science and Regulatory Affairs, aemmett(at)  

Co-Chair: Alex Azar, President, Eli Lilly, USA
Co-Chair: Kristine Peterson, Chief Executive Officer, Valeritas, Inc.
Staff Contact: Laurel Todd, Managing Director for Reimbursement and Health Policy, ltodd(at)    

Chair: Scott Kohne, Market Acceptance Manager, NAFTA, Bayer CropScience, Inc.
Vice Chair: Jeffrey Nawn, Senior Manager, Biotech Affairs and Regulatory, Dupont Pioneer
Staff Contact: Adrianne Massey, Managing Director, Food & Agriculture, amassey(at)

Chair: Ronald Stotish, Chief Executive Officer, Aqua Bounty Technologies, Inc.       
Vice Chair: Robin Readnour, Senior Director, Technology Acquisition & Biological Product Development, Elanco, Inc.
Staff Contact: Cathleen Enright, Executive Vice President, Food & Agriculture, cenright(at)